The future of 3D bioprinting by Karen Dubbin Aether Science Director

In this article looking at the future of 3D printing, Karen Dubbin discusses the emerging 3D bioprinting sector.

3D bioprinting company, Aether recently appointed Karen Dubbin as science director. With degrees from MIT and Stanford in Materials Science and Engineering Dubbin is interested in biomaterials for regenerative medicine.

Her work at Ali Khademhosseini’s lab in the Harvard/MIT HST program looked at developing small tissue mimics for high throughput drug testing using thermo responsive molds. During her time with Sarah Heilshorn’s lab at Stanford, Dubbin worked on their injectable hydrogels for both cell transplantation and bioprinting applications.

As science director at Aether, Dubbin is currently developing a line of bio-inks, which the company expects to be available late 2017.

The future of 3D printing by Karen Dubbin, Science Director at Aether

The market for 3D printing of thermoplastics, thermosets, and metals has grown rapidly over the past 10 years, making 3D printing more accessible to large companies, academic labs, and individuals. The development of desktop printers and decrease in the cost of hardware and consumables have led to an increase in accessibility for the technology.

Read more

Healthcare supply chains to digitise and automate, says new report

The automation and digitisation of healthcare supply chains will drive the development of future pharmaceutical supply chains, according to a report by DHL.

The report identified six transformational trends that would affect future healthcare supply chains: big data analytics; the internet of things; healthcare on demand; robotics and automation; augmented reality and additive manufacturing.

Bill Meahl, chief commercial officer, DHL said: “The Life Sciences and Healthcare sector is currently going through a transformational phase of its operating models and supply chains: The industry is affected by cost pressure from governments and regulatory authorities, changing consumer behaviour as well as the effects of digitalisation.”

The report states that big data will allow healthcare providers to make more informed decisions about the management of their operations by connecting all members of a healthcare system and combining data. This helps better predict demand and can cut cost and improves efficiency in Life Sciences logistics and supply chain operations.

Read more